Together, our data suggested that phosphorylation of p65 is related to ARRB1-mediated hepatocellular carcinogenesis via GSK3β/mTOR and that inhibitors of NF-κBp65 could be therapeutic targets for HCC. Here, MTOR is linked to hepatocellular carcinoma.